Corda Investment Management Upped By $1.23 Million Its Novartis Ag Adr (NVS) Stake; Abbvie (ABBV) Shorts Decreased By 7.14%

February 15, 2018 - By Henry Gaston

Corda Investment Management Llc increased Novartis Ag Adr (NVS) stake by 10.56% reported in 2017Q3 SEC filing. Corda Investment Management Llc acquired 14,437 shares as Novartis Ag Adr (NVS)’s stock rose 4.17%. The Corda Investment Management Llc holds 151,179 shares with $12.98M value, up from 136,742 last quarter. Novartis Ag Adr now has $191.90 billion valuation. The stock increased 1.30% or $1.11 during the last trading session, reaching $86.63. About 780,507 shares traded. Novartis AG (NYSE:NVS) has risen 7.67% since February 15, 2017 and is uptrending. It has underperformed by 9.03% the S&P500.

Abbvie Incorporated (NYSE:ABBV) had a decrease of 7.14% in short interest. ABBV’s SI was 14.07M shares in February as released by FINRA. Its down 7.14% from 15.15M shares previously. With 4.10 million avg volume, 3 days are for Abbvie Incorporated (NYSE:ABBV)’s short sellers to cover ABBV’s short positions. The stock increased 1.08% or $1.22 during the last trading session, reaching $114.3. About 5.52 million shares traded. AbbVie Inc. (NYSE:ABBV) has risen 10.63% since February 15, 2017 and is uptrending. It has underperformed by 6.07% the S&P500.

Among 21 analysts covering Abbvie Inc (NYSE:ABBV), 10 have Buy rating, 2 Sell and 9 Hold. Therefore 48% are positive. Abbvie Inc had 78 analyst reports since July 21, 2015 according to SRatingsIntel. The stock has “Hold” rating by BMO Capital Markets on Friday, April 28. The rating was maintained by Jefferies with “Buy” on Friday, August 18. Atlantic Securities initiated AbbVie Inc. (NYSE:ABBV) rating on Friday, December 18. Atlantic Securities has “Neutral” rating and $59 target. Cowen & Co downgraded the stock to “Market Perform” rating in Monday, June 6 report. Jefferies maintained AbbVie Inc. (NYSE:ABBV) on Monday, July 17 with “Buy” rating. The firm earned “Hold” rating on Tuesday, September 5 by Cowen & Co. The firm has “Hold” rating by BMO Capital Markets given on Wednesday, April 19. Jefferies maintained AbbVie Inc. (NYSE:ABBV) on Monday, June 26 with “Buy” rating. Goldman Sachs maintained AbbVie Inc. (NYSE:ABBV) on Friday, March 10 with “Buy” rating. The firm has “Hold” rating given on Friday, July 28 by Cowen & Co.

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company has market cap of $182.47 billion. The firm offers HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; IMBRUVICA, an oral therapy for the treatment of patients with chronic lymphocytic leukemia; and VIEKIRA PAK, an interferon-free therapy, with or without ribavirin, for the treatment of adults with genotype 1 chronic hepatitis C. It has a 34.64 P/E ratio. It also provides Kaletra, an anti- human immunodeficiency virus-1 medicine used with other anti-HIV-1 medications as a treatment that maintains viral suppression in HIV-1 patients; Norvir, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and Synagis to prevent RSV infection at-risk infants.

Since September 11, 2017, it had 0 insider purchases, and 5 selling transactions for $25.59 million activity. Shares for $14.07M were sold by Schumacher Laura J. Michael Robert A. sold $589,512 worth of stock. SALEKI-GERHARDT AZITA had sold 8,300 shares worth $705,655. Another trade for 87,040 shares valued at $8.57M was sold by RICHMOND TIMOTHY J.. On Monday, October 30 the insider Gosebruch Henry O sold $1.66M.

Investors sentiment decreased to 0.85 in 2017 Q3. Its down 0.15, from 1 in 2017Q2. It fall, as 55 investors sold AbbVie Inc. shares while 640 reduced holdings. 132 funds opened positions while 462 raised stakes. 1.06 billion shares or 1.89% more from 1.04 billion shares in 2017Q2 were reported. Cornercap Counsel reported 19,221 shares. Provident Tru holds 15,978 shares or 0.06% of its portfolio. Montag A Associates has 69,815 shares. Clearbridge Limited Liability stated it has 0% of its portfolio in AbbVie Inc. (NYSE:ABBV). First Long Island Invsts invested 2.49% of its portfolio in AbbVie Inc. (NYSE:ABBV). Rothschild Asset Management Inc stated it has 9,682 shares or 0.01% of all its holdings. Catalyst Cap Advsrs Limited Liability Company holds 0.02% of its portfolio in AbbVie Inc. (NYSE:ABBV) for 3,927 shares. Lagoda Inv L P, a New York-based fund reported 489 shares. Dowling Yahnke Limited Liability Company accumulated 75,896 shares. Rbo, California-based fund reported 109,168 shares. Laurion Capital Mgmt L P holds 0.01% of its portfolio in AbbVie Inc. (NYSE:ABBV) for 17,996 shares. Livingston Asset Management (Operating As Southport Capital Management) has invested 0.49% in AbbVie Inc. (NYSE:ABBV). Bartlett And Co Limited Liability Corporation holds 0.5% or 135,442 shares in its portfolio. Baxter Bros Inc holds 0.06% in AbbVie Inc. (NYSE:ABBV) or 2,499 shares. Godshalk Welsh Cap Mgmt stated it has 0.74% of its portfolio in AbbVie Inc. (NYSE:ABBV).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Posts